TP53 and myeloproliferative neoplasm: To understand the transcriptional signatures associated with leukemic progression, we analyzed samples from 5 CP-MPN patients who subsequently developed TP53-sAML (pre-TP53-sAML) alongside 6 CP-MPN patients harboring TP53-mutated clones who remained in CP (CP TP53-MPN, median 4.43 years (2.62–5.94) of follow-up; Fig. 4a and Extended Data Fig. 8).